Algert Global LLC Increases Stock Position in Schrödinger, Inc. (NASDAQ:SDGR)

Algert Global LLC lifted its holdings in Schrödinger, Inc. (NASDAQ:SDGR) by 45.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 126,760 shares of the company’s stock after buying an additional 39,540 shares during the quarter. Algert Global LLC owned approximately 0.17% of Schrödinger worth $2,351,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of SDGR. Vanguard Group Inc. increased its stake in shares of Schrödinger by 0.5% during the first quarter. Vanguard Group Inc. now owns 6,809,024 shares of the company’s stock valued at $183,844,000 after purchasing an additional 32,393 shares in the last quarter. CANADA LIFE ASSURANCE Co increased its position in Schrödinger by 5.2% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 68,995 shares of the company’s stock valued at $1,861,000 after buying an additional 3,410 shares in the last quarter. Virtu Financial LLC purchased a new position in Schrödinger during the first quarter valued at $263,000. GAMMA Investing LLC boosted its holdings in Schrödinger by 49.5% in the second quarter. GAMMA Investing LLC now owns 2,124 shares of the company’s stock worth $41,000 after acquiring an additional 703 shares in the last quarter. Finally, Nisa Investment Advisors LLC grew its stake in shares of Schrödinger by 145.3% in the second quarter. Nisa Investment Advisors LLC now owns 1,413 shares of the company’s stock worth $27,000 after acquiring an additional 837 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Schrödinger Trading Down 3.8 %

NASDAQ:SDGR opened at $21.46 on Wednesday. The company has a market cap of $1.56 billion, a PE ratio of -9.17 and a beta of 1.50. The company has a 50 day simple moving average of $18.68 and a two-hundred day simple moving average of $20.17. Schrödinger, Inc. has a 12 month low of $16.67 and a 12 month high of $38.00.

Schrödinger (NASDAQ:SDGR) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.12). Schrödinger had a negative return on equity of 35.77% and a negative net margin of 91.84%. The firm had revenue of $35.30 million during the quarter, compared to the consensus estimate of $41.25 million. During the same period in the previous year, the firm earned ($0.86) EPS. The business’s revenue was down 17.1% on a year-over-year basis. Research analysts forecast that Schrödinger, Inc. will post -2.29 earnings per share for the current year.

Insider Transactions at Schrödinger

In related news, insider Margaret Dugan sold 1,531 shares of the firm’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $17.78, for a total value of $27,221.18. Following the transaction, the insider now directly owns 13,469 shares of the company’s stock, valued at approximately $239,478.82. This trade represents a 10.21 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 8.60% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on SDGR. BMO Capital Markets lifted their price target on Schrödinger from $25.00 to $28.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. Morgan Stanley cut their price target on shares of Schrödinger from $43.00 to $30.00 and set an “equal weight” rating on the stock in a report on Wednesday, August 21st. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $32.90.

Schrödinger Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.